In December, one form 483 was posted, issued to Sun Pharmaceuticals in Halol, India. The 483 is 16 pages long and includes 8 observations, including detailed issues with the micro laboratory. We cover the form 483 below.
And, we reviewed the Govzilla Store to see which 483s were most-purchased and trending during December.
[NOTE: Are you interested in learning more about observations with specific industry keywords? Get your FREE 483 Observation Report and you can quickly determine who has been hit with the same observations. Learn more here!]
DRUG FIRM | Sun Pharmaceuticals
Sun Pharmaceuticals site in Halol, India received a 16-page, 8 observation form 483 at the close of inspection on December 13, 2019. Three investigators conducted the inspection. Observation #4 is noted as a repeat from a previous inspection. I would not be surprised to see a warning letter follow from this inspection based on the topics covered and that it identifies very detailed problems associated with aseptic processing and the micro laboratory.
Observations include but are not limited to:
- The Quality Unit does not implement adequate and validated controls to ensure that products meet the quality they are purported to. While this observation, #1 in the list, is fairly well redacted it appears to concern a collection of OOS events where the root cause was not identified.
- The Quality Unit failed to implement controls over computer systems that would prevent environmental monitoring data in the QC laboratory from being manipulated. This includes EM data associated with manufacture of sterile products. The observation provides four pages of detail. Any firm using a similar system to the MODA-EM system would be well advised to read through this.
- The firm apparently didn’t follow their own procedure in testing for quality attributes. While the observation is well redacted, it seems that fewer vials were included in the evaluation than should have been.
- Swab samples of equipment in the sterile area are not adequately described in the procedure. Thus it is unclear what is and isn’t sampled based on the procedure.
- Aseptic processing areas are not subject to adequate environmental monitoring. This observation describes shortcomings in the online particle count sampling location risk assessment.
- Visual inspection of filled drug product vials is inadequate.
- The Quality Unit did not respond effectively to a large number of critical equipment alarms.
Anazaohealth Corporation (Las Vegas, NV) received a form 483 at the close of inspection on September 19, 2019.
M Drug, LLC, dba Northern Light Pharmacy
M Drug, LLC, dba Northern Light Pharmacy (Bangor, ME) received an amended form 483 issued at the close of inspection on August 20, 2019.
Mandell’s Clinical Pharmacy
Mandell’s Clinical Pharmacy (Somerset, NJ) received a form 483 at the close of inspection on July 25, 2019.
Nubratori Inc dba Nubratori Rx
Nubratori Inc dba Nubratori Rx (Torrance, CA) received a form 483 based on an inspection ending September 26, 2019.
SBH Medical LTD
SBH Medical LTD (Worthington, OH) received a form 483 at the close of inspection on September 30, 2019.
Govzilla Store’s Most Purchased Individual 483s
[NOTE: With a 483 Observation Report, you can quickly determine if there’s a citation trend you should be aware of. Learn more here!]
Contact us if you ever have questions at firstname.lastname@example.org.